One potential noninvasive approach for antenatal diagnosis is the use of fetal cells in maternal circulation as a source of fetal DNA (1 ) . To date, fetal DNA has been extracted from maternal nucleated blood cells and amplified by nested PCR of Y-chromosome sequences from male fetuses (2, 3 ) .
A recent study (4 ) demonstrated the presence of fetal DNA in maternal plasma. After a single PCR with a high number of cycles, detection of fetal DNA was possible in 24 (80%) of the 30 maternal plasma samples, using 10 L of boiled plasma (4 ) . When DNA extracted from a similar volume of whole blood was used, only 17% of the samples gave a Y-positive signal, suggesting an enrichment of fetal DNA in plasma compared with whole blood cells (4 ) . The mechanism responsible for fetal DNA release in maternal circulation is unclear. It has been postulated that fetal cell lysis after physical and immunological damage, as well as developmentally regulated apoptosis of certain fetal tissues, may be responsible for this phenomenon (5 ) . Furthermore, the release and clearance of fetal DNA from maternal plasma may be influenced by pathophysiological factors that are still to be determined.
The efficacy of the single PCR protocol on maternal plasma DNA has not yet been compared to established methodologies of nested amplification of DNA prepared from intact cells. The present work compares single PCR on plasma DNA with nested PCR on DNA extracted from plasma or nucleated blood cells. We collected 27 maternal blood samples at gestational ages ranging from the 7th to the 32nd weeks (16 male-and 11 female-bearing pregnancies). Nine, 14, and 4 samples were from the first (7-12 weeks), second (14 -20 weeks), and third (27-32 weeks) trimesters. Fetal gender was unknown at the time of sampling and analysis and was verified at delivery. After informed consent was given, 6 mL of maternal peripheral venous blood were collected into a Vacutainer blood tube (product no. 15057; Becton Dickinson System Eur) containing EDTA. DNA extraction from either plasma or blood cells was performed as described (4, 6 ) .
All PCR reactions were performed in an Omnigene Hybaid Thermalcycler. Nested PCR, both on plasma and blood cell DNA, was performed as follows: For the first PCR, 2 g of maternal blood-cell DNA or 10 L of plasma was amplified with primers Y1.5 and Y1.6 (Boehringer) (3 ) . PCR was performed in a 100-L mixture containing 10 mmol/L Tris-HCl (pH 8.8), 2.5 mmol/L MgCl 2 , 50 mmol/L KCl, 15 mL/L Triton X-100, 20 mol/L each dNTP (Pharmacia), 2 U of DyNAzyme II DNA polymerase (Finnzymes Oy), and 20 pmol of each primer. Cycling conditions included 1 cycle of 5 min at 94°C, followed by 40 cycles of 1 min at 94°C, 1 min at 57°C, and 1 min at 72°C. For the second PCR, 2 L of the first PCR product was re-amplified in 50 L of fresh reagents for 35 cycles of 1 min at 94°C, 1 min at 57°C, and 1 min at 72°C (4 ) with the primer pair Y1.7-Y1.8 (198-bp fragment) (3 ).
For single PCR, 10 L of maternal plasma was amplified with primers Y1.5 and Y1.6 (239-bp fragment) as above but with 15 pmol of each primer. We used 60 cycles of Hot Start PCR with 1 min at 94°C and 1 min at 57°C. At the 30th cycle, 2 U of DNA Polymerase and 15 pmol of the primer pair were added. The products (10 L) were electrophoresed in a 2% agarose ethidium bromidestained gel.
We amplified 6 and 3 pg of male DNA as positive controls. All samples giving Y-negative results were further amplified for an autosomal locus. For each of the three protocols, each sample was tested in duplicate in two different PCR sessions (quadruple testing, 324 total amplifications) (7 ) . Samples at least two times positive in the four amplifications were considered as positive (male fetuses). To eliminate contamination, all PCR reagents were aliquoted and irradiated with ultraviolet light and pre-and post-PCR reaction areas were separated. To eliminate contact with exogenous male DNA, only female operators performed all procedures. All manipulations were carried out with disposable material and frequent changes of gloves.
The two nested approaches on plasma (Fig. 1A) or on blood cells (Fig. 1B ) generated sharp bands, whereas single PCR on plasma sometimes engendered a smear, which could not be interpreted (Fig. 1C, lane2 ). Because this phenomenon had never been observed in the nested PCR protocol, in which a maximum of 40 cycles is used for each set of primers, we concluded that it may be a characteristic of PCR protocols having a higher number of cycles, in which nonspecific products may become predominant. This is also supported by the presence of the smear in samples corresponding to female-bearing pregnancies. Table 1 summarizes results obtained with the three methods. For each sample, the final interpretation of quadruple testing is reported. We previously demonstrated that a multiple testing protocol substantially improves PCR accuracy and predictive values in fetal gender determination (7 ) . Fetal male DNA from both plasma and blood cells could be amplified by the three methods during all three trimesters of pregnancy. No false-negative results were obtained with nested PCR on plasma DNA. Single PCR on plasma DNA produced positive results for all samples corresponding to male-bearing pregnancies except for one, which gave a smear after PCR and thus was noninterpretable (case 9 in Table 1 ). On the other hand, five false-negative results were obtained on the same samples by nested PCR on blood cells. These last results referred to samples collected during the second trimester. This is not surprising because we previously demonstrated a drop in fetal DNA detection from the first to the second trimester, suggesting a variable concentration of fetal cells in maternal blood, with a negative balance in the second trimester (6 ) . In the present study, we could not demonstrate a similar variable concentration of fetal DNA from maternal plasma, either because fetal DNA release in maternal plasma is constant in the first and second trimesters or because the concentration is above our plasma PCR detection limit in both trimesters. On samples obtained from female-bearing pregnancies, no false-positive results were obtained with nested PCR on blood cell DNA, and only one false-positive result was obtained with nested PCR on plasma DNA. Conversely, with single PCR on plasma DNA, we obtained four false-positive results. We attributed the high-false positive rate of the single PCR to the higher number of cycles used to amplify fetal DNA compared with nested PCR, coupled with the double opening of the tube first for the addition of enzyme during the hot start, and then for the addition of enzyme and primers halfway through the PCR cycles, both of which are crucial for the efficiency of the reaction. Using single PCR on plasma DNA, we obtained two noninterpretable results because the samples produced smear (cases 21 and 26, Table 1 ).
The sensitivity (95% confidence intervals) of the three PCR methods was 100% (76 -99%) for nested PCR of plasma DNA; 94% (68 -99%) for single PCR on plasma DNA, similar to that reported (80%) (4 ); and 69% (42-88%) for nested PCR on blood cell DNA. The specificity (95% confidence intervals) of the three PCR methods was 100% (68 -99%) for nested PCR on blood cell DNA, 45% (18 -75%) for single PCR on plasma DNA, and 91% (57-99%) for nested PCR on plasma DNA. Nested PCR on plasma DNA had the highest number of correct identifications of fetal sex, although the difference was not statistically significant. We favor the use of nested PCR on plasma. A nested protocol does not imply any additional contamination risk and is no more time-consuming than a single 60-cycle hot-start PCR. The use of cellular material appears to offer no advantages in sensitivity over plasma. Plasma could thus be a naturally enriched, accessible, and useful material for the detection of fetal DNA sequences that does not require any extensive purification.
This work was supported in part by Bio-Rad Laboratories (M.F.) Several genes such as the genes that code for apolipoprotein E4, amyloid ␤-precursor protein, and presenilin 1 and 2 have been linked to the development of Alzheimer disease (AD) (1 ) . Recently, a polymorphism of the human ␣ 2 -macroglobulin gene (A2M) was also identified as a risk factor for AD (2 ) . The A2M gene is located on chromosome 12p13.3-p12. 3 (3 ) , and its product (␣ 2 -macroglobulin) is a serum pan-proteinase inhibitor occurring in many organs and tissues (4 ) . Several studies have suggested that ␣ 2 -macroglobulin may have protective effect against the deposition of ␤-amyloids (5, 6 ) and may stimulate their degradation (7, 8 ) . A 5-nucleotide deletion mutation at the 5Ј splice site of "exon II" of the bait region (exon 18; A2M-2) may lead to loss of this protection because of its location at the functional domain, and this loss confers increased risk for AD (2 ) . Currently available methods based on DNA sequencing (2, 9 ), heteroduplex formation in nondenaturing gel (9 ), and PCR-restriction fragment length polymorphism (10 ) for detection of this deletion mutation are all relatively cumbersome for routine use in clinical laboratories. Here, we describe a semi-automated PCR-single-stranded conformational polymorphism (PCR-SSCP) detection method that is amenable to use for largescale screening.
Detection of a Deletion Polymorphism of the Human
Genomic DNA was extracted from EDTA-anticoagulated whole blood using the QIAamp blood kit (Qiagen). The A2M target DNA sequence was PCR amplified by modifying a previously described technique (9 ). The 5Ј upstream primer was 5Ј-CTT TCC TTG ATG ACC CAA GCG CC-3Ј, and the 3Ј downstream primer was 5Ј-GTT GAA AAT AGT CAG CGA CCT C-3Ј. The PCR conditions were as follows: 37°C for 10 min; 95°C for 9 min; 30 cycles of 94°C for 1 min, 59°C for 40 s, and 72°C for 40 s. The PCR reaction mixture of 100 L contained 1 g of human genomic DNA, 20 pmol of each primer, 200 mol/L dNTPs, 2.5 mmol/L MgCl 2 , 50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 8.3), 0.1 g/L gelatin, and 3 U of Gold AmpliTaq polymerase (Perkin-Elmer). In addition, 5 mol/L dUTP (Perkin-Elmer) and 10 kU/L uracil glycosylase (Perkin-Elmer) were added to the PCR mixtures to prevent contamination.
The PCR products were checked for purity by electrophoresis in 1% agarose gel followed by ethidium bromide staining. Images of the patterns were captured with a CCD camera (COHU) coupled with NIH image 1.62 software (NIH). The 326-bp PCR band was quantified by comparison to a DNA gel marker (Research Genetics).
